Salin Amponnavarat, M.D.

Post-doctoral Research Fellow @mayoclinic | Heme/Onc enthusiast | Global health | MD'24 @Ramathibodi

[Stephen V Liu, MD @StephenVLiu]

Landmark, practice changing study at #WCLC26. The phase III MAVERICK study shows no improvement in OS with PCI for SCLC, across limited and extensive stages, with worse cognitive failure free survival and increased toxicity in PCI arm.

The end of the PCI era.

[Sakditad “Tew” Saowapa, MD @SakditadMD]

Just published! ✨🔬
Our systematic review on the inappropriate use of tumor markers (CA-125, CA 19-9, CEA, AFP, CA 15-3) in asymptomatic people is out in Asian Pac J Cancer Prev.

Low PPV, lots of false positives, extra scans/procedures, and no proven mortality benefit. We also propose a simple follow-up algorithm for incidental elevations. 📌🌸
Evidence over reflex testing. 💡🧬

#CancerScreening #TumorMarkers @oncodaily @hemeoncfellow @HemOncFellows @IMG_Oncologists

https://t.co/k15facs2K9

[Karamvir Yadav @K_Yadavir]

What changed in metastatic driver-positive NSCLC?

The 2026.3.3 ASCO Living Guideline highlights:

• Sunvozertinib for EGFR exon 20 insertions
• Broad tissue/liquid NGS, ideally with RNA
• No single-agent ICI for activating EGFR alterations
• Re-biopsy/NGS at progression
• Increasing options across HER2, ROS1, NRG1 and other drivers

A useful update for everyday lung cancer practice.

#NSCLC #LungCancer #MedicalOncology #PrecisionMedicine @OncodailyLung

[Toni Choueiri, MD @DrChoueiri]

JUST IN: The SAFFRON trial is + for PFS and OS via @AstraZeneca —NSCLC, EGFR-mutated with MET over expression post EGFR-m progression

https://t.co/TbdmI9F7gn

[Erman Akkus @Erman_Akkus]

Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysis - ESMO Open https://t.co/3fvKNgeL1m

[Carmine De Angelis @CarmineDeA1]

🏅Optimal treatment sequencing after CDK4/6i + ET in HR+/HER2− MBC remains unclear due to lack of head-to-head trials 🤔
💻We conducted a systematic review & NMA to guide evidence-based decisions.
📰Read more: https://t.co/3QUFaERmUw
@OncoAlert
@oncodaily
@eClinicalMed

[Paolo Tarantino @PTarantinoMD]

Answer: according to a recent large study, over 80% of HER2-zero (IHC 0) breast cancers actually exhibit some staining, qualifying for being considered HER2-ultralow.
Ref: https://t.co/pPzvI4R4Ni

[Allison Fitzgerald, MD, PhD @allisonoconn]

My med student just asked if NK cells are a type of T cell!!! 😭😭💔💔 like a dagger through my heart.

[Matteo Lambertini, MD PhD @matteolambe]

Out in @JAMA_current huge academic effort to clarify role of #TILs tumor-infiltrating lymphocytes to avoid #chemotherapy in some patients with triple-negative #BreastCancer: honored & grateful to have @UniGenova @SanMartino_Ge part of it!
@OncoAlert #bcsm

https://t.co/PEU9xULwvt

[Rami Manochakian MD, FASCO @RManochakian]

🔥🚨Hot off the press.

The #FDA approves 1st line #Osimertinib WITH chemotherapy for advanced #EGFRm non-small cell #LungCancer.

Approval based on #FLAURA2 trial which showed ⬆️#PFS compared to #Osimertinib alone.

HR: 0.62
mPFS: 25.5 vs 16.7 months

👇🏼
https://t.co/QRxAgEZgDD

[Randaline Barnett, MD 🧠🧸🦄 @rbarnettmd]

I walked into a patient’s room today, and the patient’s mom asked, “Are you the surgeon who braids hair?”

“Yes! Yes I am!” 😊

“We heard all about you! We are so excited!!”

🥹🥹🥹

Another little patient of mine jumped out of their bed and came straight to me to give (1/3)

[Vincent Rajkumar @VincentRK]

I would like to share the story of how a patient with cancer came up with the idea for a randomized trial, & how listening to him saved a lot of lives.

1/ In 2002, I had just completed a randomized trial with the notorious drug thalidomide for the cancer, multiple myeloma.

[Thanat Chaikijurajai, MD @TChaikijurajai]

I am so thrilled and happy to share that I have couples matched at @MayoCVFellows @MayoClinicCV for #CardiologyFellowship with my partner @Taopitchaya!!! Can’t wait to start our next journey together 😊 #Match2024

[Thanakit Suebsaicharoen @thanakitsueb]

On the first day of #AHA23, we got a great opportunity to learn from many professors and colleagues who came to visit our posters. We will surely bring back comments and suggestions to improve our study.

[uché blackstock, md @uche_blackstock]

BREAKING NEWS: Alarmed by increasing diagnoses in young women and high death rates in Black women, the U.S. Preventive Services Task Force is recommending all women at average risk for breast cancer get their regular mammograms at age 40 instead of age 50.
https://t.co/R8X5LX93A8

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

In this paper published today @JCOGO_ASCO we describe lessons learned from a survey of Canadian GPOs on how GPs can be effectively trained and utilized under the task-sharing and task-shifting models to care for an patients with cancer. https://t.co/CO48TKpmJV @QueensGlobalOnc

[Salin Amponnavarat, M.D. @SalinAmpn]

Submitted my application to #ESMO course for medical student today. Incredibly excited and keeping my fingers crossed for the end of May!

[Charles Swanton @CharlesSwanton]

If risk factors are not driving cancer by a mutagenic mechanism, how are they acting? This paper by Riva et al suggests many @IARC carcinogens could act in a non-mutagenic way. https://t.co/K3mzvkIRuZ

[Charles Swanton @CharlesSwanton]

Tumour promotion was first proposed by Berenblum & Shubik and developed by Allan Balmain and others. Thank you to Prof Balmain for this excellent N&V https://t.co/WasMLTsrA1

[Charles Swanton @CharlesSwanton]

Today our important study on air pollutants in the promotion of lung cancer has been published in @Nature led by @WillHilliam @LimEmilia @DrClareWeeden @SwantonLab ...Thread below🧵https://t.co/q1ICykmVox